The superior cervical ganglion (SCG) represents the largest and most rostral ganglion in the sympathetic chain, serving as a critical relay station for autonomic innervation of the head and neck region. This postganglionic sympathetic neuron cluster plays essential roles in regulating pupillary diameter, salivation, vasoconstriction, and sweat gland activity. Recent research has revealed that the SCG is also vulnerable to neurodegenerative processes, particularly in synucleinopathies, making it an important structure in understanding the autonomic manifestations of neurodegenerative diseases. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Autonomic Nervous System | [4]
| Location | Neck, at the C2-C3 vertebral level, posterior to the carotid sheath | [5]
| Cell Types | Postganglionic sympathetic neurons, small intensely fluorescent (SIF) cells |
| Primary Neurotransmitter | Norepinephrine |
| Secondary Transmitters | ATP, neuropeptide Y |
| Key Markers | Tyrosine hydroxylase (TH), Dopamine beta-hydroxylase (DBH), PHOX2B, peripherin |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:4033102 | superior cervical ganglion TH neuron | Medium |
| Cell Ontology | CL:4033103 | superior cervical ganglion NPY neuron | Medium |
| Cell Ontology | CL:4033105 | superior cervical ganglion SST neuron | Medium |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:4033102 | superior cervical ganglion TH neuron |
The SCG is situated at the apex of the lung, at the level of the second and third cervical vertebrae. It is the most rostral (uppermost) ganglion in the sympathetic chain and is typically oval or fusiform in shape, measuring approximately 20-25 mm in length in adults. The ganglion sits posterior to the carotid sheath and is bordered by:
The SCG contains several neuronal populations:
| Neuron Type | Target | Function |
|---|---|---|
| Pupillodilator neurons | Iris dilator muscle | Pupillary dilation |
| Vasoconstrictor neurons | Cerebral and extracranial vessels | Blood flow regulation |
| Secretomotor neurons | Salivary glands | Salivation |
| Pilomotor neurons | Arrector pili muscles | Hair erection |
| Sudomotor neurons | Sweat glands | Thermoregulation |
The SCG receives sympathetic preganglionic input from:
The SCG projects to diverse targets:
Ocular structures:
Cranial structures:
Vascular targets:
Other targets:
SCG neurons exhibit characteristic electrophysiological properties:
The SCG is significantly affected in Parkinson's disease and contributes to multiple pathological features:
Autonomic dysfunction: SCG degeneration contributes to:
Pupillary abnormalities: Reduced pupillary light reflex and abnormal pharmacologic responses
Lewy body pathology: The SCG is among the peripheral autonomic neurons affected early in PD (Braak staging)
REM sleep behavior disorder: Autonomic dysfunction in RBD correlates with SCG impairment
The SCG undergoes severe neuronal loss in multiple system atrophy (MSA):
While primarily affecting central cholinergic systems, AD can also involve peripheral autonomic structures:
Autonomic symptoms management:
Neuroprotective strategies:
The study of Superior Cervical Ganglion Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Braak H, et al. Staging strategy for the development of Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211. 2003. ↩︎
Jellinger KA. Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Mov Disord. 2014;29(14):1704-1714. 2014. ↩︎
Kaufmann H, Goldstein DS. Pure autonomic failure: a restricted dysautonomia. Clin Auton Res. 2013;23(5):243-245. 2013. ↩︎
Saper CB, German DC, White CL 3rd. Neuronal pathology in the nucleus basalis and associated cell groups in Parkinson's disease: possible implications for treatment. J Neural Transm Suppl. 1987;24:203-211. 1987. ↩︎
Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: what we know and what we need to know. Mov Disord. 2012;27(12):1506-1515. 2012. ↩︎